ClinicalTrials.gg
CompletedNCT05586958EURELIA1Updated Oct 29, 2025

Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients

A Phase 3 interventional study of Tigulixostat and Placebo in Gout, Hyperuricemia and Gout Flare, sponsored by LG Chem. Completed at 52 sites in 4 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-10-29.

Sponsored by LG Chem · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2024, 2 years ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Oct 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
354
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Gout by LG Chem — none open to participants now, none under way, none of them phase 3. Gout · LG Chem.

Enrollment
2nd of 11
354 · median 37
Started
2022
the only one that year
Phase 3
2 of 11
none open now
Registered
9th of 11
by date

Among the 11 studies in Gout by LG Chem, this one is the 2nd largest by enrollment, is the only one that started in 2022, is one of 2 in phase 3, and was the 9th registered.

Gout

347 studies on the registry are indexed under Gout; 50 are open to participants now.

Browse Gout studies →

Open to participants now

None of the 11 studies in Gout by LG Chem is open now. The open studies under Gout, anywhere →

Who these studies take

Of the 31 Gout studies recruiting now, 14 (45%) set no upper age limit and 10 (32%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Gout by LG Chem as a file.
02

Study summary

The aim of this 6-month randomized multi-regional double-blind parallel group placebo-controlled phase 3 study is to assess the efficacy and safety of three different doses of Tigulixostat in gout patients with hyperuricemia.

03

Conditions studied

  • Gout
  • Hyperuricemia
  • Gout Flare
  • Tophi

Browse trials for

Keywords

  • Gout
  • Hyperuricemia
  • Xanthine Oxidase Inhibitor
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects between the ages of 18 85 years, inclusive.
  • Subjects with hyperuricemia and a history or presence of gout per American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) 2015 criteria.
  • Subjects who are currently on urate-lowering therapies (ULT) with an sUA level ≥6.0 mg/dL at screening (Visit 1); or subjects who are currently not on ULT with an sUA level ≥7.0 mg/dL at screening (Visit 1). Subjects currently on ULT will undergo washout and must have an sUA level ≥7.0 mg/dL at Visit 3 to be randomized and participate in the study.
  • Subjects with a ≤50 kg/m2 and estimated (eGFR) ≥30 mL/min/1.73 m2 at screening (Visit 1).

Exclusion criteria

Exclusion Criteria:

  • Subjects with secondary hyperuricemia, enzymatic defects.
  • Subjects experiencing an acute gout attack (intense pain, swelling, or/and tenderness in the joint area) within 2 weeks prior to screening (Visit 1).
  • Subjects who have received pegloticase to treat gout which has not responded to the usual treatments.
  • Subjects who have not been receiving stable doses of drugs known to affect sUA levels for the last 3 weeks prior to screening (Visit 1).
  • Subjects with a history of xanthinuria (elevated levels of xanthine in the urine) and rheumatoid arthritis
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
354 participants (actual)

Study arms

  • Experimental
    Tigulixostat 100mg

    Tigulixostat 100mg, Once a day (QD) for up to 6 months

    Drug: Tigulixostat

  • Experimental
    Tigulixostat 200mg

    Tigulixostat 200mg, Once a day (QD) for up to 6 months

    Drug: Tigulixostat

  • Experimental
    Tigulixostat 300mg

    Tigulixostat 300mg (100mg + 200mg), Once a day (QD) for up to 6 months

    Drug: Tigulixostat

  • Placebo comparator
    Placebo

    Placebo, Once a day (QD) for up to 6 months

    Drug: Placebo

Interventions

  • Xanthine Oxidase Inhibitor

    Also known as: LC350189

  • DrugPlacebo

    Matching placebo

06

What researchers measure

Primary outcomes

  1. The proportion of subjects with sUA levels <6.0 mg/dL sustained at months 4, 5, and 6

    Serum uric acid (sUA) level will be measured at Month 4,5, and 6

    Time frame: Up to Month 6

Secondary outcomes

  1. The proportion of subjects with sUA levels <5.0 mg/dL sustained at months 4, 5, and 6

    Serum uric acid (sUA) level will be measured at Month 4,5, and 6

    Time frame: Up to Month 6

  2. The proportion of subjects reporting a gout flare up to each visit.

    Gout flare (intense pain, swelling, or/and tenderness in the joint area) will be assessed from baseline up to 6 months

    Time frame: Up to Month 6

  3. Incidence rate of adverse event

    Safety assessment

    Time frame: Up to Month 6

07

Study locations

52 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • Medvin Clinical Research
    Covina, California 91722, United States
  • Clinical Research of West Florida, Inc.
    Clearwater, Florida 33765, United States
  • Herco Medical and Research Center, Inc
    Coral Gables, Florida 33134, United States
  • Direct Helpers Research Center
    Hialeah, Florida 33012, United States
  • Allied Biomedical Research Institute
    Miami, Florida 33155, United States
  • Research Institute of South Florida, Inc.
    Miami, Florida 33173, United States
  • Clinical Research of West Florida, Inc.
    Tampa, Florida 33606, United States
  • Conquest Research, LLC
    Winter Park, Florida 32789, United States
  • Vista Clinical Research, LLC
    Newnan, Georgia 30265, United States
  • Velocity Clinical Research
    Meridian, Idaho 83642, United States
  • Healthcare Research Network II, LLC
    Flossmoor, Illinois 60422, United States
  • Alliance for Multispecialty Research, LLC
    Lexington, Kentucky 40509, United States
  • L-MARC Research Center
    Louisville, Kentucky 40213, United States
  • MD Medical Research
    Oxon Hill, Maryland 20745, United States
  • Elite Clinical Research, LLC
    Jackson, Mississippi 39202, United States
  • Olive Branch Family Medical Center
    Olive Branch, Mississippi 38654, United States
  • Practice Dr. David Headley
    Port Gibson, Mississippi 39150, United States
  • HealthCare Research
    Hazelwood, Missouri 63042, United States
  • Healor Primary Care/CCT Research
    Las Vegas, Nevada 89102, United States
  • Meridian Clinical Research, LLC
    Vestal, New York 13850, United States
  • Triad Clinical Trials
    Greensboro, North Carolina 27410, United States
  • STAT Research
    Vandalia, Ohio 45377, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Tristar Clinical Investigations, P.C.
    Philadelphia, Pennsylvania 19114, United States
  • Velocity Clinical Research Greenville
    Greenville, South Carolina 29615, United States
  • PCCR Solutions
    Colleyville, Texas 76034, United States
  • Pioneer Research Solutions, Inc.
    Houston, Texas 77099, United States
  • Endeavor Clinical Trials
    San Antonio, Texas 78240, United States
  • DM Clinical Research
    Tomball, Texas 77377, United States
  • Highland Clinical Research
    Salt Lake City, Utah 84124, United States
  • South Ogden Family Medicine/CCT Research
    South Ogden, Utah 84405, United States
  • Velocity Clinical Research, Salt Lake City
    West Jordan, Utah 84088, United States
  • Meridian Clinical Research, LLC
    Portsmouth, Virginia 23703, United States
  • Dominion Medical Associates, Inc.
    Richmond, Virginia 23219, United States
  • Clinical Research Partners, LLC
    Richmond, Virginia 23226, United States
  • LTD "Clinic LJ"
    Kutaisi, 4600, Georgia
  • Aleksandre Aladashvili Clinic LLC
    Tbilisi, 0102, Georgia
  • LTD Israel-Georgian Medical Research Clinic Helsicore
    Tbilisi, 0112, Georgia
  • JSC "Vian"
    Tbilisi, 0159, Georgia
  • LTD MediClub Georgia
    Tbilisi, 0160, Georgia
  • LTD Multiprofile Clinic Consilium Medulla
    Tbilisi, 0186, Georgia
  • Angeles University Foundation Medical Center
    Angeles, 2009, Philippines
  • Davao Doctors Hospital
    Davao City, 8000, Philippines
  • Lipa Medix Medical Center
    Lipa, 4217, Philippines
  • Makati Medical Center
    Makati, 1229, Philippines
  • Manila Doctors Hospital
    Manila, 1000, Philippines
  • ManilaMed - Medical Center
    Manila, 1000, Philippines
  • Phramongkutklao Hospital
    Bangkok, 10400, Thailand
  • Ramathibodi Hospital, Mahidol University
    Bangkok, 10400, Thailand
  • Siriraj Hospital
    Bangkoknoi, 10700, Thailand
  • Thammasat University Hospital
    Khlong Luang, 12120, Thailand
08

References and documents

Publications

  • Saag KG, Dalbeth N, Hsu CY, Kuo CF, Nuki G, Perez-Ruiz F, White WB, Hariri A, Lee Y, Jang Y, Han S, Choi HK. Evaluation of the efficacy and safety of a novel xanthine oxidase inhibitor, tigulixostat, in gout patients with hyperuricemia: Design of the EURELIA 1 and EURELIA 2 studies. Contemp Clin Trials. 2025 Apr;151:107843. doi: 10.1016/j.cct.2025.107843. Epub 2025 Feb 8. PubMed 39929260 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Nov 2024, 24 months.

Of 21 phase 3 interventional studies under Gout, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 25. This study's 24 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2022
First posted
Oct 19, 2022
StartActual
Oct 25, 2022
Primary completionActual
Nov 4, 2024
CompletionActual
Dec 16, 2024
Results delay requested
Oct 23, 2025
Last update
Oct 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05586958
Lead sponsor
LG Chem
Responsible party
Sponsor
First posted
Oct 19, 2022
Start date
Oct 25, 2022
Primary completion
Nov 4, 2024
Completion
Dec 16, 2024
Last update
Oct 29, 2025

Study contacts

Hyungjin Cho, MD
study director · LG Chem

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tigulixostat

Start the discussion